FILING ANALYSIS · THURSDAY, NOVEMBER 12
InspireMD, Inc. NSPR — 8-K: Results of Operations and Financial Condition
neutral
InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System, which is expected to approximately double the U.S. addressable market, and reported $2.2 million in revenue for the third quarter, a 9% increase year over year internationally, but an 11.1% decrease overall compared to the same period last year.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →